BRENTWOOD, Tenn. / Jul 19, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (f/k/a Ardent Health Partners, LLC and collectively “Ardent Health” or the “Company”), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the closing of its initial public offering (the “Offering”) of 12,000,000 shares of its common stock sold by the Company at a public offering price of $16 per share, for total gross proceeds of approximately $192 million, before deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 1,800,000 shares at the public offering price, less underwriting discounts and commissions.
Ardent Health intends to use the net proceeds from the Offering for working capital, to acquire complementary businesses, products, services or technologies and for general corporate purposes, which may include repayment of debt and capital expenditures. The Company’s common stock began trading on the New York Stock Exchange on July 18, 2024, under the ticker symbol “ARDT.”
J.P. Morgan, BofA Securities and Morgan Stanley acted as lead book-running managers for the Offering. Stephens Inc., Citigroup, Leerink Partners, RBC Capital Markets, Truist Securities, and Mizuho acted as bookrunners. Capital One Securities and Loop Capital Markets acted as co-managers.
A registration statement on Form S-1 (the “Registration Statement”) relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”). A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. This offering was made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it. and This email address is being protected from spambots. You need JavaScript enabled to view it.; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC, 28255-0001, Attn: Prospectus Department, by telephone at 800-294-1322 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often identify forward-looking statements. These forward-looking statements, including statements regarding the use of proceeds, are subject to a number of risks, uncertainties, and assumptions, including those described under "Risk Factors" in Ardent Health’s Registration Statement. Except as required by law, Ardent Health has no obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
About Ardent Health
Ardent Health is a leading provider of healthcare in growing midsize urban communities across the country. With a focus on people and investments in innovative services and technologies, Ardent Health is passionate about making healthcare better and easier to access. Through its subsidiaries, Ardent Health delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 providers across six states.
Last Trade: | US$16.27 |
Daily Volume: | 562,645 |
November 06, 2024 August 14, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB